EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status

Vincent Lo Re iD, Craig W Newcomb, Dean M Carbonari iD, Alyssa K Mezochow, Sean Hennessy, Christopher T Rentsch iD, Lesley S Park, Janet P Tate, Norbert Bräu, Debika Bhattacharya, Joseph K Lim, Catherine Mezzacappa und 5 weitere

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.70069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Vincent Lo Re und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Proton Pump Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAAA NIH HHS, NIDDK NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Studies evaluating the hepatic safety of medications have been limited by the inability to control for confounding from receipt of other hepatotoxic drugs.

Objective

The objective of this study was to develop an index (Hepatotoxicity Score) to adjust for concomitant hepatotoxic medication exposure within pharmacoepidemiology studies.

Methods

We identified 193 medications with ≥ 4 reports of hepatotoxicity and created cohorts of outpatient initiators in the Veterans Health Administration (2000–2021). Exposure occurred from initiation through 30 days after discontinuation or up to 1 year. We measured age‐/sex‐adjusted rates of hospitalization for severe acute liver injury (ALI) by chronic liver disease (CLD), identified drugs with high rates, and used these rates as weights in the score. To demonstrate real‐world use, we calculated the score for proton pump inhibitor (PPI) initiators. We summed the weights of the drugs dispensed within 90 days prior to PPI initiation. Hazard ratios (HRs) of severe ALI (95% confidence intervals) were measured with and without adjustment for Hepatotoxicity Score.

Results

Among 89 512 PPI initiators with CLD, HRs of severe ALI were higher for lansoprazole (HR = 2.17 [95% CI, 1.24–3.82]), but not pantoprazole (HR = 0.83 [95% CI, 0.61–1.13]), versus omeprazole. Adjustment for Hepatotoxicity Score attenuated HRs of lansoprazole (HR = 1.99 [95% CI, 1.13–3.50]). Among 2 462 414 PPI initiators without CLD, HRs were not significantly higher for lansoprazole (HR = 1.66 [95% CI, 0.99–2.77]) but were significantly lower for pantoprazole (HR = 0.59 [95% CI, 0.37–0.95]), versus omeprazole. Adjustment for Hepatotoxicity Score attenuated HRs of lansoprazole (HR = 1.52 [95% CI, 0.91–2.54]).

Conclusions

The Hepatotoxicity Score provides a tool to adjust for confounding due to concomitant hepatotoxic drug exposure within hepatic safety studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemical and Drug Induced Liver InjuryProton Pump InhibitorsHumansMaleFemaleMiddle AgedAgedUnited StatesPharmacoepidemiologyChronic DiseaseHospitalizationLiver DiseasesUnited States Department of Veterans AffairsCohort StudiesAdult

Stichwörter der Autor:innen

acute liver injuryconfoundinghepatotoxicity

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Real-World Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of…
  • Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
  • US Department of Veterans Affairs, VA Connecticut Healthcare System, West Haven, Connecticut, USA.
  • Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California, USA.

ORCID-Profile: Vincent Lo Re, Dean M Carbonari, Christopher T Rentsch, Jason A Roy, Jessie Torgersen

Förderung

  • NIAAA NIH HHS
  • NIDDK NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NCATS NIH HHS
  • National Cancer Institute
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Lo Re, V., Newcomb, C. W., Carbonari, D. M., Mezochow, A. K., Hennessy, S., Rentsch, C. T., Park, L. S., Tate, J. P., Bräu, N., Bhattacharya, D., Lim, J. K., Mezzacappa, C., Njei, B., Roy, J. A., Taddei, T. H., Justice, A. C., & Torgersen, J. (2024). Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70069

Vancouver

Lo Re V, Newcomb CW, Carbonari DM, Mezochow AK, Hennessy S, Rentsch CT, et al. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70069

BibTeX
@article{LoRe2024,
  author = {Lo Re, Vincent and Newcomb, Craig W and Carbonari, Dean M and Mezochow, Alyssa K and Hennessy, Sean and Rentsch, Christopher T and Park, Lesley S and Tate, Janet P and Bräu, Norbert and Bhattacharya, Debika and Lim, Joseph K and Mezzacappa, Catherine and Njei, Basile and Roy, Jason A and Taddei, Tamar H and Justice, Amy C and Torgersen, Jessie},
  title = {Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.70069}
}
Kostenlos starten →